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metabolite serum concentrations in order to maintain a
steady-state concentration near 100 ~g/ml. Based on in vitro
experiments' the latter was considered adequate for
formation of tumouricidal rooperol concentrations. For most
patients a daily dose of 2 400 mg (4 capsules 3 times a day)
was sufficient.
This study was initiated and sponsored by Essential Sterolin
Products according to an agreement entered into with the
University of Stellenbosch.
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A phase I trial of hypoxoside
as an oral prodrug for
cancer therapy - absence
of toxicity
B. J. Smit, C. F. A1brecht, R. W. Liebenberg,
P. B. Kruger, M. Freestone, L. Gouws, E. Theron,
P. J. D. Bouic, 5. Etsebeth, P. P. van Jaarsveld
Objective. To assess the toxicity of hypoxoside taken
orally by 24 patients with lung cancer.
Design. Open study with patients taking 1 200 - 3 200
mg standardised Hypoxis plant extract (200 mg capsules)
per day divided in 3 doses in order to maintain metabolite
blood levels near 100 ~g/ml.
Participants and setting. Patients with histologically
proven squamous, large-cell or adenocarcinoma were
hospitalised initially at the radiation oncology ward, Kart
Bremer Hospital, Bellville, W. Cape. Thereafter they
returned every 2 weeks for full clinical examinations.
Methods. Routine biochemical and haematological
measurements were done. Patients underwent regular full
clinical examinations including radiographs and computed
tomography scanning according to the discretion of the
principal investigator.
Results. Nineteen patients on hypoxoside therapy
survived for an average of 4 months with progression of
their primary tumours and metastases, while 5 survived for
more than a year. One of them survived for 5 years and
histological examination of the primary lesion showed
absence of cancer. No toxic effects, in clinical
examinations or biochemical or haematological
measurements, were found that could be ascribed to the
ingestion of hypoxoside. Only one occasion of possible
drug intolerance, with anxiety, nausea, vomiting and
diarrhoea, was noted.
Departments of Radiotherapy and Pharmacology, University of .
Stellenbosch, Tygerberg, w. Cape
B. J. Smit M.MED.
C. F. A1brecht. PHD.
P. B. Kruger, PH.D.
L Gouws, M.MED.
E. Theron, M.SC.
P. J. D. Bouic, PH.D.
S. Etsebeth, M.SC
P. P. van Jaarsveld, PH.D.
Essential Sterolin Products, Halfway House, Gauteng
R. W. Liebenberg, B.COMM.
M. Freestone, R.N.
SAMJ Volume 85 No.9 September 19-95~
Rgure 1
Hypoxoside as a non-toxic prodrug
Fig. 1. Hypoxoside as a non-toxic prodrug for cancer therapy.
The quantitative sequestration of rooperol metabolites in
the bile of experimental animals such as the mouse, rat and
dog,' however, excluded their use as an in vitro anticancer
Conclusion. The absence of toxicity warrants further
investigation of hypoxoside'as an oral prodrug, especially
in patients with slow-growing necrotising tumours that are
inoperable and have high concentrations of 13-
glucuronidase and sulphatase as well as a high sensitivity
for rooperol.
S Afr Med J 1995; 85: 865-870.
Patient eligibility
Patients above 21 years of age with histologically proven
squamous cell, large-cell or adenocarcinoma of the
bronchus were included after informed consent according to
the Declaration of Helsinki had been obtained. Patients with
impaired renal, hepatic or cardiac function or inadequate
performance status (H2 or lower) and those who, in the
opinion of the investigator, had less than 3 months to live
were excluded. The only concomitant anticancer therapy
allowed was palliative radiotherapy.
model for hypoxoside. We therefore obtained permission
from our Ethics Committee and the Medicines Control
Council to conduct a phase I clinical trial in 24 lung cancer
patients for whom no alternative therapy was available.
The first part of the trial included a study of the
pharmacokinetic behaviour of the metabolites.8A wide
interpatient variation in concentration-time relationships was
found which can be explained by active enterohepatic
recirculation, a lag phase in absorption and saturable
conversion of hypoxoside to rooperol in the colon.
However, the elimination of the metabolites follows
predictable first-order kinetics with acceptable half-life
values (20 - 50 hours). In the toxicity part of the study, - t
which we wish to report here, maintenance doses were
individualised for patients in order to obtain metabolite levels
near 100 ~g/ml. This concentration was found to be
cytotoxic in vitro after enzymatic activation.'
Hypoxoside was supplied by Essential Sterolin Products as
a standardised plant extract in capsule form, each capsule
containing 200 mg of plant extract. Quality control was
assured by high-performance liquid chromatography (HPLC)
as described earlier.',8 The hypoxoside content of the
standardised plant extract ranged from 50% to 55%.8
Routine monitoring of metabelite serum levels was done
using the HPLC methodology described by Kruger et a/.9
Material and methods
Medication and monitoring of serum
metabolite levels
The patients were hospitalised at the radiation oncology
ward, Karl Bremer Hospital, Bellville, W. Cape, for the
duration of the pharmacokinetic studies. During the long-
term therapy stage they returned to hospital every 2 weeks
and underwent full clinical examinations including
radiographs and computed tomography (CT) scanning
according to the discretion of the principal investigator.
.,
Laboratory analyses
Biochemical and haematological analyses were performed
by the chemical pathology and haematology laboratories at
Tygerberg Hospital, Tygerberg, W. Cape.
Study design
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Fig. 1 summarises the major results of our research on
hypoxoside.'·3 It is non-toxic to cancer cells in tissue culture,
but when deconjugated to rooperol significant cytotoxicity is
found at relatively low concentrations. After oral ingestion no
hypoxoside or rooperol are found in the circulation.' Only
phase 11 metabolites (glucuronides and sulphates) of
rooperol are present. Like the glucoside, the conjugated
me.tabolites are also non-toxic to cells in tissue culture, but
they can be activated by treatment with glucuronidase.'
Since it is known that certain tumours contain relatively high
levels of glucuronidase4-7 activation of rooperol metabolites
at the site of the tumour therefore seemed to be an
attractive approach to achieve selectivity in cancer
chemotherapy. ""
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Table 11. Number of patients in the trial at various time intervals
(refer to Figs 2 - 4)
Biochemical and haematological data
Figs 2 - 4 provide summaries of all the biochemical and
haematological data collected from the patients while they
were on long-term therapy. The vertical bars fn the figures
represent the mean ± 1 standard deviation (SD) of the value
measured during intervals of approximately 30 days.
Since 19 of the 24 patients survived less than 1 year it
must be realised that the data presented in Figs 2 - 4 are
the trends of the mean values in a decreasing population.
Table 11 shows the distribution of surviving patients at
monthly intervals and hence the sample sizes at each time.
Results
Patient details
Of the 24 patients who entered the trial 14 were male and 10
female, with ages ranging from 43 to 77 years (mean 56,4
years). Histologically proven diagnoses were
adenocarcinoma (9 patients), large-cell carcinoma (9
patients) and squamous cell carcinoma (6 patients). The
average survival time. for 19 of the patients was 4 months
after entering the trial, which agreed with their prognosis
without any therapy. Most of them developed metastases.
Table I lists 5 patients who survived longer than expected.
Two of them (patients 23 and 24) showed significant arrest
of their tumour sizes. Their clinical status will be discussed
in more detail (vide infra). Time (d) No.
Values of the liver enzymes alanine transaminase (ALl),
aspartate transaminase (ASl) and lactate dehydrogenase
(LD) stayed within normal limits, while mean values of
enzymes sensitive to metastases were above normal.
Several patients also abused alcohol periodically (Fig. 2).
Long-term therapy
Because the serum metabolite concentrations showed
considerable interpatient variationS owing to apparent zero-
order formation of rooperol, the maintenance dose was
adjusted when necessary for each patient during hospital
visits in order to achieve combined metabolite blood levels
near 100 IJg/ml. According to in vitro experiments' this
concentration was considered adequate for activation of the
metabolites t6 tumouricidal rooperol concentrations. The
minimum and maximum maintenance doses required were
1 200 and 3 200 mg standardised plant extract per day
divided into 3 equ.al doses every 8 hours. For most patients
a daily dose of 2 400 mg plant extract (4 capsules 3 times a
day) was sufficient.
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Major clinical events in
. course of trial
Partial collapse of lung with small
pleural effusion. Clinically well after 5 moo
Developed widespread metastases
Clinically well except for alcohol abuse
as reflected in liver enzyme levels.
Elected to leave trial
Gradual progression of tumour.
20 Gy 8OCO on days 330 - 335 resulted in
a marked reduction of tumor size.
Developed liver metastases
Clinically well except for dyspnoea on
exertion. Death due to cerebrovascular
haemorrhage
Large tumour with destruction of
3 - 5 ribs. Clinically well except for
sporadic alcohol abuse. CT scan showed
reversal of rib destruction after 2 yrs.
Died of TB pneumonia. Histological
examination of autopsy material showed
absence of cancer
Table I. Details of patients entered in the trial who survived longer than expected
Survival time (mo.)
From On Medical treatment
Patient no. Age (yrs) Sex Diagnosis diagnosis trial before entering trial
20 47 F Large-cell 22 19,5 50 Gy 8OCO
carcinoma
21 54 M Large-cell 15 13,3 Partial resection
carcinoma
22 57 M Squamous 15,5 12 Inoperable tumour
carcinoma
23 77 M Squamous 42 35 50 Gy 8OCO
carcinoma
24 49 M Adeno- 63 60 25 Gy 8OCO
carcinoma
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Fig. 3. Serum protein concentrations of all the patients in the
trial, plotted as in Fig. 2.
increased marginally and the Iymphocyte count decreased
slightly. The platelet count stayed remarkedly constant.
The absence of any adverse effect of hypoxoside on the
values reported above has been verified by specialists in the
Departments of Chemical Pathology and Haematology at
Tygerberg Hospital.
Fig. 2. Liver enzyme activity of all the patients in the trial. Each
point represents the average of all values obtained on a monthly
basis with 1 SO shown as a vertical bar. The shaded areas depict 15
the upper and lower normal limits for the population.
5
Fig. 3 shows the trend observed with serum proteins. The
relatively low albumin and increased acute-phase protein
concentrations (notably a-globulins) are clearly linked to the
disease state of the patients. Serum electrolytes (Na+, K.,
CI-, Ca2+) and serum creatinine and urea concentrations were
mostly within normal limits except for sporadic deviations
during terminal phases.
Fig. 4 summarises the haematological profiles of the
patients. These values are usually grossly affected by
chemotherapeutic agents used in the treatment of cancer,
but it is clear that hypoxoside had no negative effect on
them. The haemoglobin concentration and the white cell
count stayed constant, while the neutrophil count probably
I .~ Volllme 85 No.9 September 1995 SAMJ
o 200 400 600
DAYS ON TRIAL
.-
1-
ARTICLES
Fig. 4. Haematological profile of all the patients in the trial,
plotted as in Fig. 2.
Fig. 5. Chronological CT scans of the tumour in case 24 (Table I),
at 2 months (A) and 29 months (B) after institution of hypoxoside
therapy. Destruction of ribs 3 - 5 by adenocarcinoma (thick arrow)
was reversed during therapy. Unique opacities were used as
markers to select comparable scans.
Clinical. status of patients 23 and 24
Since these 2 patients survived the longest while on
hypoxoside they underwent a full neurological examination
together with the normal regular clinical examinations during
the 30th month. No evidence of neurotoxicity resulting from
hypoxoside ingestion was found after clinical evaluation by
the Neurology Department at Tygerberg Hospital.
Fig. 5 shows chronological CT scans of the tumour in
case 24. It is clear that the initial lesions of the ribs reversed
to a large extent, together with a reduction in original tumour
mass. During this period the alkaline phosphatase levels fell
to normal. The patient died of TB pneumonia resulting from
tuberculosis after 5 years on hypoxoside therapy
(approximately 1 g per day). Histological examination of
tissue taken at autopsy showed that all organs (kidney, liver,
bone marrow, colon, intestine, brain, spleen) were normal,
and surprisingly no cancer could be detected in the fibrotic,
cystic lesion in the lung.
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Other measurements
Regular measurements of blood pressure and temperature
showed no abnormalities. Body mass also stayed constant
except when patients developed cachexia in the terminal
phase. Serial electrocardiograms also failed to demonstrate
any evidence of cardiotoxicity of hypoxoside as confirmed
by the Cardiology Department at Tygerberg Hospital.
Side-effects
One patient experienced possible drug intolerance on day
171 of the trial when the serum concentration of hypoxoside
metabolites rose to 163 ~g/ml. Anxiety, nausea, vomiting,
diarrhoea, dyspnoea and rigors were associated with a
doubling in the LD and alkaline phosphatase values. The
patient stopped taking the drug and the symptoms subsided
after 4 - 6 hours. The dose was then reduced from 2 400 mg
to 1 200 mg per day and the drug was tolerated without
further incidents for another 36 days, after which the patient
died of cardiorespiratory failure.
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Discussion
Several reports published in the mid-1970s focused attention
on high f3-glucuronidase and sulphatase activities in
experimental tumours.4-7 The idea of designing a prodrug that
would be activated by these enzymes at its site of action is
therefore not new. However, a successful therapeutic prodrug
has yet to be developed for human use. It has been shown
that a mouse tumour with high f3-glucuronidase activity was
curable with glucuronide conjugates of aniline mustard
formed in vivo! However, the drug produced significant
anticancer activity in only 5 of 78 patients studied.'
It is not the objective of a phase I clinical trial to reach a
conclusion with regard to efficacy. In this trial 19 out of 24
patients survived as long as their estimated prognosis (4
months), while 5 survived longer than expected (12 months to
5 years). The patient who survived 5 years had no detectable
metastases. It therefore seems possible that cancer patients
who might benefit from hypoxoside are those with relatively
slow-growing necrotising tumours that are inoperable and
have high concentrations of f3-glucuronidase and sulphatase
as well as a high sensitivity for rooperol, as was found for the
H552 human adenocarcinoma cell line. f Other types of cancer
that merit investigation are tumours of the pancreas and bile
ducts. There is a verifiable anecdotal case in which a patient
with cancer of the pancreas on hypoxis plant extract is still
alive 10 years after diagnosis. It could be argued that cancer
of the pancreas might result in significant deconjugating
enzyme release to activate the hypoxoside metabolites
sufficiently for the aglucone to act as an effective cytotoxic
agent. However, the major conclusion of this trial is that
short- and long-term therapy (up to 5 years) with relatively
high hypoxoside dosages did not result in any obvious toxic
effect. This is not only important for further clinical studies on
the anticancer potential of hypoxoside; we llave also found
that the sulphated metabolites of rooperol show significant in
vitro and in vivo anti-HIV activity. A report on its stabilising
effect on CD4 cell numbers in HIV-positive patients will be
presented separately.
This study was initiated and sponsored by Essential Sterolin
Products according to an agreement entered into with the
University of Stellenbosch.
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Targeted chemotherapy for
parasite infestations in rural
black preschool children
M. Taylor, G. Pillai, J. D. Kvalsvig
Objective. To investigate whether targeted chemotherapy
can reduce parasite prevalence rates in rural black
preschool children.
Design. The study consisted of a before/after trial. Stool
and urine samples were analysed on four occasions over a
21-week period.
Setting. Creches in two rural areas of southern _
Kwazulu/Natal (coastal and inland). .:?
Patients. Two hundred children of 4 - 6 years of age
attending 19 creches in the area. .~
Intervention. Targeted chemotherapy using albendazole
for nematode infestations, praziquantel for trematode and
cestode infestations and metronidazole for protozoal
infections was administered twice at an interval of 14 weeks.
Main outcome measure. Prevalence rates.
Results. The prevalences of Ascaris lumbricoides,
Trichuris trichiura and Necator americanus infestation
decreased significantly after treatment. Reinfestation rates
12 weeks after treatment were 16% for A lumbricoides,
33% for T. trichiura, 24% for Giardia lambJia and 3% for N.
americanus. No reinfestation was noted for Schistosoma
haematobium, Hymenolepsis or Taenia species.
Conclusion. The study suggests that parasite
prevalence rates in children can be reduced by the
administration of appropriate chemotherapy at regular
intervals. However, the provision of clean water and
adequate sewerage facilities remains a high priority for
black communities living in rural areas of South Africa.
S Afr Med J 1995; 85: 870-874.
Although the mortality rate associated with parasite
infestations is negligible, morbidity such as impaired
physical and mental development is significant. This is
confirmed by studies on nematode and cestode infestation
in children.'-3 In Jamaica prevalence and intensity of infection
with Trichuris trichiura were found by Nokes et aJ! to be
greater among academically less able pupils. Boivin et al. 5
reported that after successful treatment for infestation with
serious types of chronic intestinal parasites children in Zaire
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